Engineering Newcastle disease virus as oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines.
Newcastle Disease Virus (NDV) is an attractive candidate for oncolytic immunotherapy due to its ability to replicate in tumor cells and potentially overcome the inherently immunosuppressive nature of the tumor microenvironment. The advent of checkpoint blockade immunotherapy over the past few years represents a paradigm shift in cancer therapy. However, the prevalence of severe immune-related adverse events with CTLA-4 and PD1 pathway blockade in clinical studies especially in combination therapy groups, is a cause for concern. Immunotherapies with cytokines have also been extensively explored but they have been associated with adverse events in clinical trials. Oncolytic vectors engineered to express checkpoint blockade antibodies and cytokines could provide an avenue for reducing the clinical toxicity associated with systemic therapy by concentrating the immunomodulatory payload at the site of disease. In this study, we engineered six different recombinant viruses, NDVs expressing checkpoint inhibitors (rNDV-anti-PD1 and rNDV-anti-PDL1), superagonists (rNDV-anti-CD28) and immunocytokines, where these antibodies are fused to an immunostimulatory cytokine such as IL12 (rNDV-anti-CD28-mIL12, rNDV-anti-PD1-mIL12 and rNDV-anti-PDL1-mIL12). These six engineered viruses induced tumor control and survival benefit both in a highly aggressive unilateral and bilateral B16-F10 murine melanoma model, indicative of an abscopal effect. The data represent a strong proof-of-concept, on which further clinical evaluation could build.IMPORTANCE Checkpoint inhibitor therapy has shown tremendous efficacy but also frequent and often severe side effects-especially when multiple drugs of this class are used simultaneously. Similarly, many investigational immunotherapy agents, which have shown promise in animal models, have failed in clinical trials due to dose-limiting toxicity when administered systemically. This study utilized a murine melanoma model to evaluate the efficacy of intratumoral injections of recombinant NDVs engineered to express multiple immunotherapeutic proteins with well-documented side effects in humans. Our results indicate that intratumoral administration of these recombinant NDVs, particularly when combined with systemic CTLA4 checkpoint inhibition, exerts a robust effect in treated and non-treated tumors indicative of a systemic anti-tumoral response. The intratumoral delivery of rNDVs expressing immunotherapeutic proteins may be an effective method of targeting immune cell populations most relevant for anti-tumoral immunity and allowing to restrict the use of systemic immunotherapy agents.